Boston, United States
Psy Therapeutics is at the forefront of biotechnological innovation, aiming to transform treatment landscapes for neuropsychiatric and neurodegenerative disorders. Established in 2012, their mission encapsulates creating "new futures in central nervous system (CNS) treatment and care."
The company's strategic edge lies in its strong pipeline of novel small molecules that leverage innovative platform technologies. This targeted approach has yielded highly brain-penetrant and well-tolerated molecules, effectively addressing the limitations of current treatments. The science-driven methodology is underpinned by both clinical and preclinical evidence, highlighting a risk-contained development plan.
With investment momentum gained from a Seed Round investment on 05 April 2022 led by Ayuh Ventures, Psy Therapeutics showcases compelling potential. Managed by an accomplished team of biopharma executives, clinicians, and neuroscience experts, the firm is well-positioned for significant advancements in mental and neurological healthcare.
Psylo